Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, will present at the 2026 ThinkEquity Conference on October 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. CEO and Executive Chairman Ehud Geller will provide an overview of the company’s GelrinC technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration pivotal Phase III trial, and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings with investors.
The presentation matters because it offers investors a direct look at Regentis’ lead product, GelrinC, a cell-free, off-the-shelf hydrogel implant that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. GelrinC aims to address a U.S. market of approximately 470,000 cartilage knee repair cases annually where no off-the-shelf treatment is available. With the Phase III trial underway and European commercialization preparations advancing, the company is positioning itself to potentially capture a significant share of this unmet need.
Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone, with an initial focus on orthopedic treatments. The company’s participation in the ThinkEquity Conference comes as it seeks to raise its profile among investors and industry stakeholders. Full details of the announcement are available through Regentis Biomaterials (NYSE American: RGNT) and the complete press release can be viewed at https://ibn.fm/wicmT.
The news was distributed by MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com, and see full terms of use and disclaimers at https://www.MissionIR.com/Disclaimer.
For Regentis, the ThinkEquity presentation represents a key opportunity to communicate its clinical and commercial momentum to a targeted investor audience. As the company moves closer to potential U.S. regulatory approval and European market entry, its ability to attract investment and partnerships could accelerate the adoption of GelrinC and address a substantial unmet need in orthopedic care.
